Insmed price target raised to $90 from $63 at Barclays

Barclays analyst Leon Wang raised the firm’s price target on Insmed to $90 from $63 and keeps an Overweight rating on the shares. The firm’s survey of pulmonologists suggests a $6B peak opportunity for bronchiectasis under reasonable pricing and penetration. This “unmodeled upside provides additional runway” for Insmed, the analyst tells investors in a research note.